Search

Your search keyword '"Palumbo, Raffaella"' showing total 7 results
Start Over Author "Palumbo, Raffaella" Publisher springer science and business media llc
7 results on '"Palumbo, Raffaella"'

1. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

Author

Torrisi, Rosalba, primary, Palumbo, Raffaella, additional, De Sanctis, Rita, additional, Vici, Patrizia, additional, Bianchi, Giulia Valeria, additional, Cortesi, Laura, additional, Leonardi, Vita, additional, Gueli, Rossana, additional, Fabi, Alessandra, additional, Valerio, Maria Rosaria, additional, Gambaro, Anna Rita, additional, Tagliaferri, Barbara, additional, Pizzuti, Laura, additional, Cazzaniga, Marina Elena, additional, and Santoro, Armando, additional

Published
2021
Full Text
View/download PDF

2. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

Author

Biganzoli, Laura, primary, Cinieri, Saverio, additional, Berardi, Rossana, additional, Pedersini, Rebecca, additional, McCartney, Amelia, additional, Minisini, Alessandro Marco, additional, Caremoli, Elena Rota, additional, Spazzapan, Simon, additional, Magnolfi, Emanuela, additional, Brunello, Antonella, additional, Risi, Emanuela, additional, Palumbo, Raffaella, additional, Leo, Silvana, additional, Colleoni, Marco, additional, Donati, Sara, additional, De Placido, Sabino, additional, Orlando, Laura, additional, Pistelli, Mirco, additional, Parolin, Veronica, additional, Mislang, Anna, additional, Becheri, Dimitri, additional, Puglisi, Fabio, additional, Sanna, Giuseppina, additional, Zafarana, Elena, additional, Boni, Luca, additional, and Mottino, Giuseppe, additional

Published
2020
Full Text
View/download PDF

3. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)

Author

Passalacqua, Rodolfo, primary, Lazzarelli, Silvia, additional, Donini, Maddalena, additional, Montironi, Rodolfo, additional, Tambaro, Rosa, additional, De Giorgi, Ugo, additional, Pignata, Sandro, additional, Palumbo, Raffaella, additional, Ceresoli, Giovanni Luca, additional, Del Conte, Gianluca, additional, Tonini, Giuseppe, additional, Morelli, Franco, additional, Nolè, Franco, additional, Panni, Stefano, additional, Rondini, Ermanno, additional, Guida, Annalisa, additional, Zucali, Paolo Andrea, additional, Doni, Laura, additional, Iezzi, Elisa, additional, and Caminiti, Caterina, additional

Published
2017
Full Text
View/download PDF

4. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study

Author

Arpino, Grazia, primary, Michelotti, Andrea, additional, Truini, Mauro, additional, Montemurro, Filippo, additional, Russo, Stefania, additional, Palumbo, Raffaella, additional, Zamagni, Claudio, additional, Latorre, Agnese, additional, Bruzzese, Dario, additional, Riccardi, Ferdinando, additional, De Laurentiis, Michelino, additional, Beano, Alessandra, additional, Biganzoli, Laura, additional, Zaniboni, Alberto, additional, Laudadio, Lucio, additional, Malagoli, Maria, additional, Bilancia, Domenico, additional, Schettini, Francesco, additional, Giuliano, Mario, additional, Cazzaniga, Marina Elena, additional, and De Placido, Sabino, additional

Published
2015
Full Text
View/download PDF

6. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin

Author

Venturino, Antonella, primary, Comandini, Danila, additional, Simoni, Carlotta, additional, Merlini, Laura, additional, Naso, Cinzia, additional, Palumbo, Raffaella, additional, Fusco, Vittorio, additional, Porcile, Gianfranco, additional, Pronzato, Paolo, additional, Rosso, Riccardo, additional, and Repetto, Lazzarono, additional

Published
2000
Full Text
View/download PDF

7. Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)

Author

Laura Pizzuti, Laura Cortesi, Barbara Tagliaferri, Armando Santoro, Patrizia Vici, A. Gambaro, Rita De Sanctis, Raffaella Palumbo, Alessandra Fabi, Vita Leonardi, Rosalba Torrisi, Maria Rosaria Valerio, Rossana Gueli, Marina Elena Cazzaniga, Giulia Bianchi, Torrisi, R, Palumbo, R, De Sanctis, R, Vici, P, Bianchi, G, Cortesi, L, Leonardi, V, Gueli, R, Fabi, A, Valerio, M, Gambaro, A, Tagliaferri, B, Pizzuti, L, Cazzaniga, M, Santoro, A, Torrisi, Rosalba, Palumbo, Raffaella, De Sanctis, Rita, Vici, Patrizia, Bianchi, Giulia Valeria, Cortesi, Laura, Leonardi, Vita, Gueli, Rossana, Fabi, Alessandra, Valerio, Maria Rosaria, Gambaro, Anna Rita, Tagliaferri, Barbara, Pizzuti, Laura, Cazzaniga, Marina Elena, and Santoro, Armando

Subjects
HER2 positive, Oncology, Cancer Research, medicine.medical_specialty, Settore MED/06 - Oncologia Medica, Receptor, ErbB-2, Advanced breast, Breast Neoplasms, Breast cancer, Maintenance therapy, Trastuzumab, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Fulvestrant, Retrospective Studies, Hormone receptor positive, business.industry, Cancer, Middle Aged, medicine.disease, Italy, Cohort, Advanced breast cancer, Female, Pertuzumab, business, medicine.drug
Abstract

Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3rd line in 67 patients. Among the 86 evaluable patients, 6 (6.9%) achieved CR, 18 (20.7%) PR, and 44 (50.6%) had SD ≥ 24 weeks with an overall CBR of 78.2%. At a median follow-up of 33.6 months, mPFS of the entire cohort was 12.9 months (range, 2.47–128.67). No difference was observed in mPFS between patients treated after progression or as maintenance therapy (mPFS 12.9 and 13.9 months in 64 and 23 patients, respectively), neither considering the number of previous treatment lines (≤ 3 or < 3). Conclusion: The combination of F and T was active in this cohort at poor prognosis and deserves further investigations possibly in combination with pertuzumab in patients with high ER expression.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results